Hold Hester Biosciences; target of Rs 2070: ICICI Direct

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

ICICI Direct's research report on Hester Biosciences

Hester is one of India’s leading animal healthcare companies & the second largest poultry vaccine manufacturer in the country. It has a strategic presence in 30+ countries with key markets being India, Nepal and Tanzania. It operates through four broad verticals: poultry vaccines, poultry health products, animal vaccines and animal health products • Revenue segment wise: poultry healthcare: 49%, animal healthcare: 51%.

Outlook

Upgraded from REDUCE to HOLD but maintain neutral stance as we monitor ramp-up in Animal Healthcare, Africa business, opportunities in pet-care to mitigate slump in legacy poultry vaccines segment. We value Hester at Rs 2070 (base business at Rs 2051 i.e. 35x FY24E EPS of Rs 58.6 + NPV of Rs 16 for Covaxin DS opportunity).

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Hester Biosciences - 08-11-2022 - icici